Table 2.
Results of subgroup analysis of the independent role of HOTAIR in OS/MFS/RFS/DFS
| Subgroup analysis | No of studies | No of patients | Pooled HR (95% CI) | Heterogeneity
|
|
|---|---|---|---|---|---|
| I2 (%) | P-value | ||||
| Overall survival | |||||
| Cancer type | |||||
| Breast cancer | 3 | 498 | 1.38 (0.36–5.27) | 87.7 | 0.000 |
| Non-breast cancer | 4 | 538 | 2.72 (1.65–4.48) | 0.0 | 0.575 |
| Ethnicity | |||||
| Caucasian | 2 | 468 | 2.55 (1.62–4.00) | 0.0 | 0.675 |
| Asian | 5 | 568 | 1.19 (0.16–8.83) | 93.6 | 0.000 |
| Preoperative treatment | |||||
| No | 5 | 568 | 1.19 (0.16–8.83) | 93.6 | 0.000 |
| Yes | 2 | 468 | 2.55 (1.62–4.00) | 0.0 | 0.675 |
| Metastasis | 2 | 296 | 2.30 (1.19–4.44) | 58.5 | 0.120 |
| Recurrence | 2 | 447 | 1.39 (0.13–14.64) | 86.2 | 0.007 |
| Disease-free | 2 | 282 | 2.53 (1.27–5.03) | 0.0 | 0.714 |
Abbreviations: CI, confidence interval; DFS, disease-free survival; HOTAIR, HOX transcript antisense intergenic RNA; HR, hazard ratio; MFS, metastasis-free survival; OS, overall survival; RFS, recurrence-free survival.